Versor Investments LP Has $207,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Versor Investments LP lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 81.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 500 shares of the company’s stock after selling 2,220 shares during the quarter. Versor Investments LP’s holdings in IDEXX Laboratories were worth $207,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Flossbach Von Storch SE increased its position in shares of IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after acquiring an additional 464,791 shares in the last quarter. Assenagon Asset Management S.A. grew its position in IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $113,104,000. Vontobel Holding Ltd. raised its stake in IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after purchasing an additional 198,404 shares during the period. Finally, Proficio Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $62,391,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Bank of America upped their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Leerink Partners began coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $441.61 on Wednesday. The stock has a market capitalization of $35.92 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.41 and a beta of 1.37. The business has a 50-day moving average of $436.35 and a two-hundred day moving average of $450.43. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $574.94. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.